Home / Research projects / A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® mg tablets administered three or two times daily to patients with diarrhoea-predominant irritable bowel syndrome
Share
A Phase II, multicentre, randomised, double-blind, placebo controlled, proof of concept study of efficacy and safety of Rifamycin SV-MMX® mg tablets administered three or two times daily to patients with diarrhoea-predominant irritable bowel syndrome
A Phase II, multicenter, randomized, double-blind, placebo-controlled, proof-of-concept study to evaluate the efficacy and safety of Rifamycin SV-MMX® 600 mg tablets administered three or twice daily to patients with diarrhea-predominant irritable bowel syndrome (IBS-D).
Project objectives
Evaluation of the efficacy and safety of rifamycin treatment in patients with irritable bowel syndrome in a phase II, multicenter, randomized, double-blind, placebo-controlled study.
Start and end date
2017 - ongoing
Project Manager
Prof. Michele Guarino
Coordinating institution of the project
Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven (international coordinating centre)
Other Institutions involved
Gastroenterology Unit, Biomedical Campus University of Rome
25 centers in 4 countries involved (Spain, Belgium, Italy, Germany)
Pharmaceutical company Cosmo Technologies Ltd (study sponsor)
L'Università Campus Bio-Medico di Roma promotes integrated teaching and research structures, pursuing the good of the person as the main aim of its activities.
